Restylane-L 1 mL; Restylane Lyft with Lidocaine 1 mL; Restylane Eyelight 0.5 mL
Q-Med AB · Decision date Jan 29, 2026
What did the FDA approve?
FDA records P040024/S143 as a supplement to PMA P040024, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jan 29, 2026.
FDA approval order statement
multiple changes including, (1) primary packaging, (2) a new needle and hub, (3) secondary packaging updates, (4) inclusion of a treatment card for recording patient and treatment information, (5) an updated IFU with updated needle assembly instructions adapted for the new syringe and the needle and information regarding the new treatment card, (6) a new syringe label, (7) a new semi-automatic downstream manufacturing line, and (8) a new transport box to fit the new smaller secondary packaging.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jan 29, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P040024/S143
- Regulatory pathway
- PMA supplement
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Jan 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040024/S143 received
Application receipt date recorded by FDA.
P040024/S144 · Related supplement
Restylane Injectable Gel
P040024/S142 · Related supplement
Restylane Lyft with Lidocaine
P040024/S146 · Related supplement
Restylane Lyft with Lidocaine
P040024/S143 · FDA decision
Normal 180 Day Track
P040024/S147 · Related supplement
Restylane Lyft with Lidocaine
P040024/S148 · Related supplement
RESTYLANE INJECTABLE GEL
Timeline entries are records held by MedtechLedger for P040024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Restylane Injectable GelP040024/S144 | Q-Med AB | PMA supplement | Sep 26, 2025 | FDA |
Restylane Lyft with LidocaineP040024/S142 | Q-Med AB | PMA supplement | Nov 4, 2025 | FDA |
Restylane Lyft with LidocaineP040024/S146 | Q-Med AB | PMA supplement | Dec 23, 2025 | FDA |
Restylane Lyft with LidocaineP040024/S147 | Q-Med AB | PMA supplement | Feb 5, 2026 | FDA |
RESTYLANE INJECTABLE GELP040024/S148 | Q-Med AB | PMA supplement | Mar 12, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, SE-752-28
Sources and methodology
- Original FDA record: P040024/S143
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





